Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David L Ennist

Showing results (1-10 of 14) with videos related to

Pageof 2
Sort By:
Muscle & Nerve|February 7, 2026
Generalizability of Edaravone EfficacyBenjamin Rix Brooks, David L Ennist, Danielle Beaulieu, et al.
Journal of Virology|April 14, 2005
Linked tumor-selective virus replication and transgene expression from E3-containing oncolytic adenovirusesMingzhu Zhu, J Andrew Bristol, Yuefeng Xie, et al.
Clinical Trials (London, England)|July 2, 2019
Design and analysis of a clinical trial using previous trials as historical controlDavid Alan Schoenfeld, Dianne M Finkelstein, Eric Macklin, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 7, 2006
CG0070, a conditionally replicating granulocyte macrophage colony-stimulating factor--armed oncolytic adenovirus for the treatment of bladder cancerNagarajan Ramesh, Ying Ge, David L Ennist, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|June 6, 2003
In vitro and in vivo activities of an oncolytic adenoviral vector designed to express GM-CSFJ Andrew Bristol, Mingzhu Zhu, Hong Ji, et al.
Amyotrophic Lateral Sclerosis & Frontotemporal Degeneration|August 5, 2021
Development and validation of a machine-learning ALS survival model lacking vital capacity (VC-Free) for use in clinical trials during the COVID-19 pandemicDanielle Beaulieu, James D Berry, Sabrina Paganoni, et al.
Annals of Clinical and Translational Neurology|November 16, 2016
Predicting disease progression in amyotrophic lateral sclerosisAlbert A Taylor, Christina Fournier, Meraida Polak, et al.
Amyotrophic Lateral Sclerosis & Frontotemporal Degeneration|December 21, 2017
Longitudinal modeling to predict vital capacity in amyotrophic lateral sclerosisSamad Jahandideh, Albert A Taylor, Danielle Beaulieu, et al.
Annals of Clinical and Translational Neurology|April 25, 2018
Improved stratification of ALS clinical trials using predicted survivalJames D Berry, Albert A Taylor, Danielle Beaulieu, et al.
Amyotrophic Lateral Sclerosis & Frontotemporal Degeneration|July 12, 2021
Evidence for generalizability of edaravone efficacy using a novel machine learning risk-based subgroup analysis toolBenjamin Rix Brooks, Erik P Pioro, Danielle Beaulieu, et al.
Pageof 2

Showing results (1-10 of 14) with videos related to

Sort By:
Pageof 2
Muscle & Nerve|February 7, 2026
Generalizability of Edaravone EfficacyBenjamin Rix Brooks, David L Ennist, Danielle Beaulieu, et al.
Journal of Virology|April 14, 2005
Linked tumor-selective virus replication and transgene expression from E3-containing oncolytic adenovirusesMingzhu Zhu, J Andrew Bristol, Yuefeng Xie, et al.
Clinical Trials (London, England)|July 2, 2019
Design and analysis of a clinical trial using previous trials as historical controlDavid Alan Schoenfeld, Dianne M Finkelstein, Eric Macklin, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 7, 2006
CG0070, a conditionally replicating granulocyte macrophage colony-stimulating factor--armed oncolytic adenovirus for the treatment of bladder cancerNagarajan Ramesh, Ying Ge, David L Ennist, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|June 6, 2003
In vitro and in vivo activities of an oncolytic adenoviral vector designed to express GM-CSFJ Andrew Bristol, Mingzhu Zhu, Hong Ji, et al.
Amyotrophic Lateral Sclerosis & Frontotemporal Degeneration|August 5, 2021
Development and validation of a machine-learning ALS survival model lacking vital capacity (VC-Free) for use in clinical trials during the COVID-19 pandemicDanielle Beaulieu, James D Berry, Sabrina Paganoni, et al.
Annals of Clinical and Translational Neurology|November 16, 2016
Predicting disease progression in amyotrophic lateral sclerosisAlbert A Taylor, Christina Fournier, Meraida Polak, et al.
Amyotrophic Lateral Sclerosis & Frontotemporal Degeneration|December 21, 2017
Longitudinal modeling to predict vital capacity in amyotrophic lateral sclerosisSamad Jahandideh, Albert A Taylor, Danielle Beaulieu, et al.
Annals of Clinical and Translational Neurology|April 25, 2018
Improved stratification of ALS clinical trials using predicted survivalJames D Berry, Albert A Taylor, Danielle Beaulieu, et al.
Amyotrophic Lateral Sclerosis & Frontotemporal Degeneration|July 12, 2021
Evidence for generalizability of edaravone efficacy using a novel machine learning risk-based subgroup analysis toolBenjamin Rix Brooks, Erik P Pioro, Danielle Beaulieu, et al.
Pageof 2